The role of m6A methylation in therapy resistance in cancer

Mol Cancer. 2023 Jun 1;22(1):91. doi: 10.1186/s12943-023-01782-2.

Abstract

Cancer therapy resistance is the main cause of cancer treatment failure. The mechanism of therapy resistance is a hot topic in epigenetics. As one of the most common RNA modifications, N6-methyladenosine (m6A) is involved in various processes of RNA metabolism, such as stability, splicing, transcription, translation, and degradation. A large number of studies have shown that m6A RNA methylation regulates the proliferation and invasion of cancer cells, but the role of m6A in cancer therapy resistance is unclear. In this review, we summarized the research progress related to the role of m6A in regulating therapy resistance in cancers.

Keywords: Cancer; Chemoresistance; Radiotherapy resistance; m6A methylation.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Epigenesis, Genetic
  • Humans
  • Methylation
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • Neoplasms* / metabolism
  • RNA / metabolism
  • RNA Splicing

Substances

  • RNA